Trial reportAsian Pacific journal of cancer prevention : APJCP2025
A Phase 2 Prospective Trial of Capecitabine Plus Oxaliplatin as First-Line Therapy for Advanced Gall Bladder Cancers.
Trial report in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIM AND
objectiveThis study aimed to evaluate the efficacy and safety of Capecitabine plus Oxaliplatin (CapOx) chemotherapy in patients with locally advanced, inoperable, or metastatic adenocarcinoma of the gallbladder. The primary objective of the study was to determine the objective tumour response rates (complete and partial). The secondary objectives included assessment of toxicity, progression free survival, and overall survival. MATERIAL AND
methodsA prospective, single-arm, phase II study was conducted at a single center between January 2021 and December 2021. Forty-three patients with histologically confirmed advanced gallbladder adenocarcinoma were enrolled. All patients received CapOx chemotherapy (Capecitabine 1000 mg/m² orally twice daily for 14 days and Oxaliplatin 130 mg/m² intravenously on day 1, every 3 weeks for six cycles). Tumor responses were assessed clinically after each cycle and radiologically after three cycles using RECIST 1.1 criteria. Treatment-related adverse events were graded per NCI CTCAE version 5. Progression-free survival (PFS) and overall survival (OS) were analyzed using SPSS version 29.
resultsAmong the 43 patients, 35 completed three or more cycles, and 19 completed six cycles. The objective response rate (ORR) was 30.2%, and the disease control rate (DCR) was 65.1%. Median OS for all patients was 7.4 months, and PFS was 5.5 months. In patients completing six cycles, median OS was 9.8 months, and PFS was 7.3 months. The most common metastatic site was the liver. Sensory neuropathy was observed in 58.1% of patients, with grade 3/4 toxicity in 16.3%. Other reported toxicities included anemia (grade 3 in four patients), biochemical abnormalities, and gastrointestinal symptoms.
conclusionCapOx chemotherapy demonstrated modest efficacy with a disease control rate of 65.1% in patients with advanced gallbladder cancer. Toxicities were generally manageable, with sensory neuropathy being the most common. Further studies are needed to validate these findings and explore additional therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.